BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee A, Lee FC. Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check. Front Med 2020;14:273-83. [PMID: 31863306 DOI: 10.1007/s11684-019-0728-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Huang PS, Liao CJ, Huang YH, Yeh CT, Chen CY, Tang HC, Chang CC, Lin KH. Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers (Basel) 2021;13:5361. [PMID: 34771525 DOI: 10.3390/cancers13215361] [Reference Citation Analysis]
2 Wang J, Huang Z, Lu H, Zhang R, Feng Q, He A, Kloczkowski A. A Pyroptosis-Related Gene Signature to Predict Patients’ Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma. Computational and Mathematical Methods in Medicine 2022;2022:1-17. [DOI: 10.1155/2022/1258480] [Reference Citation Analysis]
3 Razpotnik R, Nassib P, Kunej T, Rozman D, Režen T. Identification of Novel RNA Binding Proteins Influencing Circular RNA Expression in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:7477. [PMID: 34299096 DOI: 10.3390/ijms22147477] [Reference Citation Analysis]
4 Zhang S, Cao M, Hou Z, Gu X, Chen Y, Chen L, Luo Y, Chen L, Liu D, Zhou H, Zhu K, Wang Z, Zhang X, Zhu X, Cui Y, Li H, Guo H, Zhang T. Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma. Cancer Lett 2021;501:147-61. [PMID: 33383154 DOI: 10.1016/j.canlet.2020.12.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]